SAN FRANCISCO, June 21, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced additional pegozafermin data in non-alcoholic steatohepatitis (NASH) will be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022, to be held in London, UK on June 22-26, 2022.
Presentation details are as follows:
Abstract Title: Pegozafermin Led to Improved Liver Histology, Liver-related Non-invasive Tests and Metabolic Profile, With Favorable Safety and Tolerability, in an Open-label Cohort of a Phase 1b/2a Study in Subjects With Non-alcoholic Steatohepatitis
Abstract Number: 3535
Format: Poster presentation (#SAT-139)
Presenting Author: Rohit Loomba, MD, MHSc, Director, NAFLD Research Center, University of California San Diego
Presentation Date and Time: Saturday, June 25th 9:00 – 18:30 BST
Abstract Title: Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH)
Abstract Number: 3654
Format: Poster presentation (#SAT-143)
Presenting Author: Naim Alkhouri, MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH)
Presentation Date and Time: Saturday, June 25th 9:00 – 18:30 BST
Abstract Title: Pharmacokinetics (PK) and Pharmacodynamics (PD) of BIO89-100, a Novel GlycoPEGylated FGF21, in Nonalcoholic Steatohepatitis (NASH) Patients with Compensated Cirrhosis
Abstract Number: 1520
Format: Poster presentation (#SAT-131)
Presenting Author: Naim Alkhouri, MD, Chief of Transplant Hepatology and Director of the Fatty Liver Program, Arizona Liver Health (ALH)
Presentation Date and Time: Saturday, June 25th 9:00 – 18:30 BST
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco with operations in Herzliya, Israel. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com
